Beijing Konruns Pharmaceutical Co. Ltd. has patented new transforming acidic coiled-coil-containing protein (TACC) inhibitors described as potentially useful for the treatment of cancer.
Chong Kun Dang Pharmaceutical Corp. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors designed for use in the treatment of cancer and inflammatory disorders.
Chugai Pharmaceutical has reported a new humanized antibody (Ab, SOF-10) that targets latent TGF-β1 and selectively blocks protease- and integrin αVβ8-mediated latent TGF-β1 activation.
Researchers from Shandong First Medical University (China) and collaborators have published a comprehensive study on the screening, synthesis, structure-activity relationship and biological evaluation of 1,2,4-oxadiazole derivatives that selectively inhibit SPHK2.
At the ongoing AACR Immuno-Oncology Conference (AACR IO) in Los Angeles, Ampersand Biomedicines Inc. gave a presentation on promising results in the field regarding AMP-410, an anti-VEGF/4-1BB antibody construct that limits 4-1BB activation in VEGF-rich tumor types, thus achieving durable efficacy.
Tarapeutics Science Inc. has reported new pyrazolopyridine compounds acting as dual specificity protein kinase CLK and dual specificity tyrosine-phosphorylation-regulated kinase (DYRK) inhibitors.
East China Normal University and Fudan University have jointly discovered tricyclic pyrimidine compounds acting as adenosine A2A and/or A2B receptor antagonists.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a B-cell lymphoma 6 protein (BCL6)-targeting moiety through a linker.
RSS
